Wei Ye - Concepedia

Author

Wei Ye

Nanjing University of Chinese Medicine ORCID

Also Known As

Shengen Cheng, WEI YE, Wei Ye, Wei 巍 Ye 叶, Y E Wei, YE Wei, Ye Wei, Ye, Wei, Ying Yao

119

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Nanjing University of Chinese Medicine Southeast University Nanjing Second Hospital Nanjing University Gilead Sciences (United States)

About

Wei Ye is an author at Nanjing University of Chinese Medicine specializing in medicine, public health, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	308
2	Public Health	3	3	308
3	Engineering	2	2	133
4	Natural Sciences	1	1	118
5	Chemistry	1	1	118

Wei Ye

Publications

886

Citations

H-Index

Page 1

	Year	Citations
ANALYSIS OF ELECTRONIC CIGARETTE CARTRIDGES, REFILL SOLUTIONS, AND SMOKE FOR NICOTINE AND NICOTINE RELATED IMPURITIES Michael L. Trehy, Wei Ye, Michael E. Hadwiger, Journal of Liquid Chromatography & Related Technologies Tobacco CessationNicotine Related ImpuritiesTobacco ControlNicotine Content LabelingDrug Purity	2011	223
In-medium nucleon-nucleon cross section and its effect on total nuclear reaction cross section X. Z. Cai, Feng Jun, Shen Wen-Qing, Physical Review C Incident Energy DependenciesEngineeringNuclear PhysicsPhysicsHigh-energy Nuclear Reaction	1998	118
Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed Neuroblastoma Denah R. Taggart, Myo Han, Alekist Quach, Journal of Clinical Oncology	2009	100
Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury Yishan Zheng, Zhen Huang, Guo-Ping Yin, InfectionImmunologyCovid-19InflammationDisclaimer Statement	2020	52
Study of the Lymphocyte Change Between COVID-19 and Non-COVID-19 Pneumonia Cases Suggesting Other Factors Besides Uncontrolled Inflammation Contributed to Multi-Organ Injury Yishan Zheng, Zhen Huang, Guo-Ping Yin, SSRN Electronic Journal	2020	51
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke, Andrei R. Shustov, James Essell, Clinical Lymphoma Myeloma & Leukemia	2018	41
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study Farrukh T. Awan, Michael J. Thirman, Dipti Patel‐Donnelly, Leukemia & lymphoma/Leukemia and lymphoma	2019	36
Cervical conization of adenocarcinoma in situ: a predicting model of residual disease Katherine E. Tierney, Paul Lin, Charles A. Amezcua, American Journal of Obstetrics and Gynecology Residual DiseaseTumoral PathologyPrecancerous LesionsCervical CancerCervical Health	2013	33
Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC YanYan Wei, Wei Ye, Wei Zhao Frontiers in Physiology	2018	29
The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma Jisheng Jing, Wei Ye, Ying‐Kui Jiang, Clinical Laboratory	2017	28

Page 1